LDLR and atherosclerosis: Likewise, the activation of TGR5 by a TGR5-specific agonist significantly reduces atherosclerosis formation in Ldlr-/- mice, mainly through reduced macrophage activation and the production of pro-inflammatory cytokines as the direct result of the NF-κB pathway blockade.